


Supplemental File

Tividenofusp Alfa Treatment in a Male Sibling Pair with Non-Neuronopathic Mucopolysaccharidosis Type II

Irene J Chang,¹ Jacqueline Madden,¹ Annie Sako,¹ Jill Dwyer,¹ Daniel Fertek,² Adam Scheller,² Sharon O'Byrne,² Imanol Zubizarreta Arambarri,² Peter Chin,² Paul Harmatz¹

¹UCSF Benioff Children's Hospital, Oakland, CA, USA; ²Denali Therapeutics Inc., South San Francisco, CA, USA

Figure S1. Phase 1/2 study design



ABBREVIATIONS

6MWT, 6-minute walk test; CSF, cerebrospinal fluid; DS, dermatan sulfate; HS, heparan sulfate; JROM, joint range of motion; KABC-II, Kaufman Assessment Battery for Children, Second Edition; NfL, neurofilament light chain

**Tividenofusp alfa (DNL310) is an investigational drug and has not been approved by any health authority.
Denali Therapeutics Inc. All rights reserved 2026.**

Supplement to poster presented at *WORLDSymposium™*, February 2–6, 2026, San Diego, CA, USA